Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Choueiri TK, et al. Among authors: chehrazi raffle a. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. Lancet. 2024. PMID: 39284329 Clinical Trial.
Targeting the multifaceted BRAF in cancer: New directions.
Toye E, Chehrazi-Raffle A, Hwang J, Antonarakis ES. Toye E, et al. Among authors: chehrazi raffle a. Oncotarget. 2024 Jul 16;15:486-492. doi: 10.18632/oncotarget.28612. Oncotarget. 2024. PMID: 39018217 Free PMC article. Review.
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, Frankel P, Llamas-Quitiquit M, Hsu J, Zengin ZB, Alcantara M, Castro D, Mercier B, Chawla N, Chehrazi-Raffle A, Barragan-Carrillo R, Jaime-Casas S, Govindarajan A, Gillece J, Trent J, Lee PP, Parks TP, Takahashi M, Hayashi A, Kortylewski M, Caporaso JG, Lee K, Tripathi A, Pal SK. Ebrahimi H, et al. Among authors: chehrazi raffle a. Nat Med. 2024 Sep;30(9):2576-2585. doi: 10.1038/s41591-024-03086-4. Epub 2024 Jun 28. Nat Med. 2024. PMID: 38942995 Free PMC article. Clinical Trial.
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy.
Ebrahimi H, Battle D, Salgia NJ, Zengin ZB, Dizman N, Meza L, Bergerot CD, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu ST, Chehrazi-Raffle A, Vaishampayan U, Staehler MD, Pal SK. Ebrahimi H, et al. Among authors: chehrazi raffle a. Nutrients. 2024 May 26;16(11):1630. doi: 10.3390/nu16111630. Nutrients. 2024. PMID: 38892563 Free PMC article.
Barriers to Clinical Trial Implementation Among Community Care Centers.
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia NJ, Zengin ZB, Meza L, Chawla N, Castro DV, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer RA, Boehmer L, Pal S, Chehrazi-Raffle A. Ebrahimi H, et al. Among authors: chehrazi raffle a. JAMA Netw Open. 2024 Apr 1;7(4):e248739. doi: 10.1001/jamanetworkopen.2024.8739. JAMA Netw Open. 2024. PMID: 38683608 Free PMC article.
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK. Gebrael G, et al. Among authors: chehrazi raffle a. Eur Urol Focus. 2024 Sep;10(5):812-817. doi: 10.1016/j.euf.2024.03.006. Epub 2024 Apr 4. Eur Urol Focus. 2024. PMID: 38580524
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Alcantara MB, Tang WS, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Raffle A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal SK, Kortylewski M. Alcantara MB, et al. Among authors: chehrazi raffle a. Front Immunol. 2024 Jan 8;14:1274781. doi: 10.3389/fimmu.2023.1274781. eCollection 2023. Front Immunol. 2024. PMID: 38259453 Free PMC article.
Boosting CAR T cells with anti-tumor mRNA vaccines.
Chehrazi-Raffle A, Budde LE, Pal SK. Chehrazi-Raffle A, et al. Nat Med. 2023 Nov;29(11):2711-2712. doi: 10.1038/s41591-023-02623-x. Nat Med. 2023. PMID: 37932550 No abstract available.
42 results